Head-to-head evidence
Insulin Efsitora Alfa vs LY900014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Efsitora Alfa
Developed by Eli Lilly
NCT05275400 · Phase 3 · completed
The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.
LY900014 · Lyumjev
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · LY900014's landscape